Clinical trial NCT04722692: Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
Official title: Sentinel Lymph Node Biopsy in Ductal Cancer in Situ or Unclear Lesions of the Breast and How to Not do it. An Open-label, Phase 3, Randomised Controlled Trial. (SentiNot 2.0).
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: DCIS
Breast Cancer
Breast Neoplasms
Sentinel Lymph Node
Keywords: Sentinel Lymph Node Dissection
DCIS; Ductal Cancer In situ of the breast
Breast cancer
Superparamagnetic Iron Oxide Nanoparticles
Sentinel Lymph Node
Risk reducing mastectomy
Lead sponsor: Uppsala University
Sponsor class: OTHER
Collaborators: name: Västmanlands Hospital, Västerås, Sweden
name: Sahlgrenska University Hospital
name: University Hospital, Linkoeping
name: Skane University Hospital
name: Blekinge County Council Hospital
name: Växjö Hospital, Växjö, Sweden
name: The University of Hong Kong-Shenzhen Hospital
name: Norrlands University Hospital
name: Dalarna County Hospital, Falun, Sweden
name: Baylor College of Medicine
First posted: 2021-01-25
Enrollment: 500
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: All patients will have been injected with SPIO during the breast procedure. Those who have invasive breast cancer on final pathology will receive radioisotope and undergo SLND. Patients will be randomly allocated to one of two arms: Experimental arm (SLND will be SPIO-guided and the isotope activity will be controlled as background) and control arm (SLND will be isotope-guided and SPIO activity will be controlled as background).
Primary purpose: TREATMENT

Brief summary: The trial aims to investigate the use of superparamagnetic iron oxide (SPIO) nanoparticles as a tracer for delayed sentinel lymph node dissection (d-SLND) in patients where upfront axillary surgery (SLND) is oncologically deemed unnecessary and should be avoided. This includes but is not limited to patients with a preoperative diagnosis of ductal cancer in situ of the breast (DCIS), an unclear BIRADS 4-5 planned for diagnostic excision or women planned for risk reducing mastectomy. SPIO is injected in the primary operation, and should final specimen pathology demonstrate invasive breast cancer, only then is an operation in the axilla (d-SLND) performed.

Detailed description: The SentiNot 2.0 protocol aims to elucidate the effectivity and accuracy of the delayed sentinel lymph node dissection concept (dSLND) when upfront SLND is considered unnecessary, such as in the setting of a preoperative diagnosis of DCIS, in cases of unclear BIRADS 4 or 5 lesions that are planned for diagnostic excisional biopsy or in selected cases of risk reducing mastectomy. Acknowledging the large variance of practice in this setting, the study aims to address pragmatism to allow for inclusion. For this reason, the trial is designed separately and independently for mastectomy and breast conserving surgery, so that participating sites can recruit as fitting in their practice.

In patients included in the SentiNot 2.0 trial, SPIO (MagTrace,2.0 ml) is injected up to 24 hours preoperatively or perioperatively during primary breast surgery on patients with a preoperative diagnosis of DCIS (or suspicious lesions with no clear diagnosis of invasive cancer but, considered for SLND). The SPIO is injected close to the lesion. If injected less than 24 hours before the operation, a 5 minute massage should be performed. Planned breast surgery is performed. The transcutaneous magnetic counts by SentiMag in the axilla is measured at the end of the breast procedure, so as to allow for confirmation that SLND may be identified. Thus,the SLN is consequently marked with SPIO, but not excised.

In this manner, women that have pure DCIS on final histopathological examination have avoided unnecessary upfront SLND.

If there is underlying invasive breast cancer on final histopathological examination, SLND will be performed at a second operation (d-SLND). A preoperative injection of radioisotope (RI) RI will be added to maximize the chance to detect the SLN. SLND will start with a registration of the magnetic and isotope signal in the axilla, and the incision will be placed in relation to the signal. In patients that have undergone mastectomy, tracers are to be injected intracutaneously in the lateral part of the mastectomy scar. The routine use of blue dye (BD) is strongly advised, but is not compulsory. However, if no transcutaneous signal for SPIO and RI is measured in the axilla pre-incision, an injection of BD according local routines will be administered. Subsequently, SLND will be performed. Patients with upgrade to invasive cancer will undergo SLND, but will be randomized with an allocation ratio of 1:1 to SentiMag first or Radioactive probe first. This will mandate the "principal modality" to perform SLND. Every step of the procedure will be controlled; if the principal modality fails, then the surgeon will use the "secondary". If the principal modality succeeds, the secondary will be registered and documented.

The procedure will be divided to the following steps:

* Transcutaneous axillary signal detection
* Subcutaneous axillary detection, after the incision has been performed.
* In situ SLN identification.
* SLN retrieval ex vivo.
* Residual axillary signal ("Background counts"). If a SLND is successfully completed with the primary modality and no residual axillary signal is detected, before completing the procedure, the secondary modality will be undertaken to allow for the detection of "discordance".

Principle modalities maybe either RI or SPIO. If BD is used, dyed lymphatics should be ignored until failure with both modalities has been reached. The success of each modality, principal and secondary, will be controlled per step. If the surgeon documents principle modality failure for a given step, this is to be documented. The intention-to-treat principle will apply, but if there is failure of the modality randomized as principle, then the per-protocol-analysis principle will apply. All SLNs (magnetic, brown, radioactive, blue) will be removed. Palpable nodes may be removed according to surgeon discretion, but should be reported as such. Total technique failure has to be discussed with the patient in advance, and a plan with patient consent consisting of no-surgery, sampling, axillary dissection or treatment according to intraoperative decision has to be available. If no SLN is found, the procedure performed (axillary clearance, sampling. etc) should be discussed in advance with the patient. The SLN may be sent for frozen section in order to avoid a third operation, if SLN metastases are present.

Standard of care patients (SLND performed upfront for diagnoses included in the inclusion criteria or patients going to l-SLND without SPIO) may also be enrolled in the study prospectively as a control arm.Additionally, patient preference will be tolerated and results will be reported for study secondary and other pre-specified endpoints. Patients in the control group has to be informed that their un-identified data will be used as a comparison and, an oral consent has to be given before surgery regardless whether SLND is planned or not. This will allow for controlled real world data from a prospective control arm in fashion of a cohort.

Eligibility criteria: Inclusion Criteria:

A. Preoperative diagnosis of DCIS, of any grade and any size if planned for mastectomy.

B. Planned Risk-reducing mastectomy, if it would be considered for upfront SLND due to institutional practice or in case of an individualised recommendation.

C. Any case with a preoperative diagnosis of pre-invasive or unclear lesion, that upfront SLND would be otherwise considered, such as, but not limited to:

* Patients with a preoperative diagnosis of DCIS grade 3 any size or, DCIS grade 2 larger than or equal to 20 mm on mammography and planned for breast conserving surgery or
* Patients with a preoperative diagnosis of DCIS on core biopsy with a palpable mass on clinical examination or mass effect on radiology or
* Patients with a preoperative diagnosis of DCIS with suspicion of micro-invasion on core biopsy or
* Patients with a mammographic/ultrasound/MRI finding, suspicious for breast cancer (BIRADS 4 or 5) planned for diagnostic excision with breast conserving surgery, with no definitive diagnosis of invasive cancer or
* Patients with a preoperative diagnosis of DCIS, any grade, any size and planned for a complex oncoplastic procedure or
* Patients with a preoperative diagnosis of DCIS, any grade, any size and planned for a procedure that may compromise detection rate for a future SLND, such as, but not confined to: lesions in the upper outer quadrant or the axillary tail, removal of the nipple areola complex and so on or
* The above mentioned categories with a preoperative diagnosis of pleomorphic Lobular Cancer in Situ (pLCIS), classic Lobular Neoplasia (LN) or Atypical Ductal Hyperplasia (ADH).

Exclusion Criteria:

* Intolerance/hypersensitivity to iron, dextran compounds or SPIO
* An iron overload disease
* Patient deprived of liberty or under guardianship
* Pregnant or lactating patients

Primary outcomes:
measure: d-SLND detection rate
timeFrame: One-time (At operation)
measure: l-SLND detection rate
timeFrame: One-time (At operation)
measure: Nodal concordance
timeFrame: One-time (At operation)
Secondary outcomes:
measure: SLND avoidance rate
timeFrame: One-time (At operation)
measure: Per patient concordance
timeFrame: One-time (At operation)
measure: Malignancy rate
timeFrame: One-time (At operation)
measure: Nodal Malignancy rate
timeFrame: One-time (At operation)
Other outcomes:
measure: Shoulder Arm Morbidity
timeFrame: Baseline and 1,6,12,24 months postoperatively
measure: Cost effectiveness
timeFrame: Baseline, and at 1, 6 and 12 months postoperatively
measure: Quality-Adjusted-Life-Years (QALY)
timeFrame: Baseline, and at 1, 6 and 12 months postoperatively
measure: Health Related Quality of Life (HR-QoL)
timeFrame: Baseline, and at 1, 6 and 12 months postoperatively
measure: Breast Specific Health Related Quality of Life (HR-QoL)
timeFrame: Baseline, and at 1, 6 and 12 months postoperatively
measure: Patient reported outcomes and measures
timeFrame: Baseline, and at 1, 6 and 12 months postoperatively
measure: Disease free interval
timeFrame: 10 years
Locations:
city: Houston
country: United States
facility: Baylor College Of Medicine
state: Texas
city: Hong Kong
country: Hong Kong
facility: The University of Hong Kong-Shenzhen Hospital
city: Falun
country: Sweden
facility: Falun Lasarett
state: Dalarna
city: Växjö
country: Sweden
facility: Växjö County Hospital
state: Kronoberg
city: Lund
country: Sweden
facility: Skåne University Hospital
state: Skåne
city: Västerås
country: Sweden
facility: Västmanland County Hospital
state: Västmanland
city: Gothenburg
country: Sweden
facility: Sahlgrenska University Hospital
state: Västra Götaland
city: Uppsala
country: Sweden
facility: Uppsala University Hospital
city: Linköping
country: Sweden
facility: Linköping University Hospital
state: Östra Götaland
Study officials:
affiliation: Uppsala University
name: Andreas Karakatsanis, PhD
role: PRINCIPAL_INVESTIGATOR
References: